The NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad) was launched in 2009 to focus on clinical and translational issues relating to radiotherapy, as well as developing a portfolio of practice-changing trials, ensuring coordination across research and actively promoting the translation of discoveries into practice.

The group routinely identifies priorities in radiotherapy research and dynamic working groups are established to address each priority.

NCRI CTRad strategic priorities:

  • Translating novel discoveries to and from the clinic
  • Evaluating and optimal implementation of new radiotherapy technologies
  • Generating evidence to change practice
  • Real-world patient experience and evidence

How can I get involved?

Join the NCRI Radiotherapy Network

Group members

Prof Robert Huddart

Professor Robert Huddart


I am Professor in Urological Cancer and Honorary consultant Clinical Oncologist at the Institute ...

Professor Robert Huddart


I am Professor in Urological Cancer and Honorary consultant Clinical Oncologist at the Institute of Cancer Research (ICR) and Royal Marsden Hospital (RMH). I undertook specialist training in Clinical Oncology at the RMH in 1989 and was awarded the Frank Doyle and Rohan Williams medals to become a Fellow of the Royal College of Radiologists. In 1992, I joined the ICR to complete a PhD in the molecular biology of testicular cancer with Professor Colin Cooper. In 1995, I was appointed Senior Lecturer and Honorary Consultant in Clinical Oncology at RMH and ICR. In 2007 I was made Reader in Urological Oncology and in 2015, Professor in Urological Cancer.

My major research interest in improving the management of bladder cancer, particularly to improve conservative treatment in patients with muscle invasive bladder cancer. A major focus of my current work is the technical development of radiotherapy, including research on intensity-modulated and image-guided radiotherapy and the application of new imaging techniques. This is alongside work in selecting patients for conservative treatment, use of neoadjuvant and concomitant therapies. My second major research interests are in the management of testicular cancer with a focus on improving outcomes in high-risk disease, minimising toxicity in low-risk disease, work on survivorships issues and the genetics of testicular cancer.

I have served as Chair of the National Cancer Research Institute Testis Clinical Studies Group, Chair of the NCRI Bladder TABS Subgroup and co-chair of Workstream 3 of NCRI’s Clinical and Translational Radiotherapy and Research Working group. I jointly lead the MSc Oncology course at the ICR.